SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending as investors react to a major leadership overhaul, including the appointment of Kevin Tang as CEO, while the community anticipates potential strategic shifts and future buyout scenarios following recent institutional accumulation and aggressive insider buying. Shareholders remain focused on the company's Q4 earnings, actively debating the long-term impact of the management transition and the secretive development status of the pipeline candidate AUR-200.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund (USO) is experiencing extreme volatility as traders weigh President Trump's 48-hour ultimatum to Iran regarding the closure of the Strait of Hormuz against the high probability of an energy supply shock. Community sentiment is deeply divided, with discussions centered on whether this is a genuine geopolitical escalation leading to significantly higher prices or if the market is being manipulated by conflicting headlines and psychological warfare.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer Inc. is trending as investors debate the impact of federal indictments against former high-level employees for alleged chip-smuggling to China, with the community split between those seeing a long-term value opportunity and others warning of deeper governance and delisting risks. Despite the company stating it is not a defendant, the stock remains under extreme pressure as traders clash over whether this represents an irrational market sell-off or a fundamental breakdown of institutional trust.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

The S&P 500 is experiencing heightened volatility following conflicting reports surrounding potential de-escalation talks between the U.S. and Iran. While market participants are actively debating whether the news signals a genuine shift in geopolitical risk or serves as a strategic distraction to stabilize oil and equity prices, sentiment remains deeply divided as traders grapple with the impact of headline-driven manipulation.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is gaining momentum as investors weigh its aggressive rollout of a "Super App" and new prediction market features against bipartisan legislative attempts to restrict prediction platforms like Kalshi and Polymarket. The community remains deeply divided, with some betting on DraftKings' regulatory moat and established sports-betting dominance, while vocal critics focus on persistent share price volatility and ongoing debates over leadership's stock selling and long-term profitability.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending as investors react to a fresh $500 million bridge financing agreement with Morgan Stanley, fueling community optimism about the company's data center build-out capabilities. While bears continue to point to macro volatility and sector-wide risks, bulls are aggressively focused on insider buying and the potential for upcoming hyperscaler contract announcements to drive the stock higher.

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide (WRD) is trending following a series of bullish analyst initiations, including coverage from Bank of America and CLSA, alongside strategic institutional accumulation by Cathie Wood's ARK Invest. The community is actively discussing the company's aggressive global robotaxi expansion in the Middle East and Singapore, with investors closely watching for the upcoming Q4 earnings report to see if this momentum translates into sustained revenue growth and market share gains.

Ambitions Enterprise Management Co. LLC operates as a travel agency. It provides event planning and management services. The firm also offers transportation, accommodations, meals, and guided tours or activities under convenient packages. The company was founded on October 26, 2023 and is headquartered in Dubai, United Arab Emirates.

Ambitions Enterprise Management Co LLC - Ordinary Shares - Class A

Ambitions Enterprise Management Co LLC

Ambitions Enterprise Management Co. is seeing massive volatility and high trading volume, fueling intense community debate over whether the stock is a legitimate short-squeeze candidate or a manipulated pump-and-dump scheme. Investors are closely monitoring the low-float action and recent event-service partnerships as the stock experiences rapid price swings and frequent trading halts.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is trending as investors react to its recent NYSE listing, with the community actively debating the premium relative to net asset value and the impact of the six-month lock-up period on the tradable float. Traders are closely monitoring the fund's exposure to high-profile private AI and tech companies, fueling speculation about potential price volatility and long-term valuation.

AleAnna, Inc. operates as a technology-driven energy company, which engages in supplying low-carbon natural gas and renewable natural gas to Italy. The company was founded in 2007 and is headquartered in Dallas, TX.

AleAnna Inc. - Ordinary Shares - Class A

AleAnna is trending as retail investors capitalize on extreme volatility fueled by Middle East geopolitical tensions and major disruptions to global LNG infrastructure. The community is heavily divided, with active debates centered on whether the price action represents a sustainable supply-side play or a coordinated short squeeze susceptible to aggressive manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Hudson Bay Capital Management LP Lowers Stake in Moderna, Inc. $MRNA

Hudson Bay Capital Management LP reduced its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 26.7% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 55,000 shares of the company's s...

Biotech Stocks Worth Watching - March 22nd

Danaher, Vertex Pharmaceuticals, and Moderna are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies whose primary business is biotechnology developing drugs, biologics, diagnostics, gene therapies, or other lifescience t...

Promising Biotech Stocks To Keep An Eye On - March 21st

Danaher, Vertex Pharmaceuticals, Moderna, United Therapeutics, ImmunityBio, argenex, and Medpace are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech...

Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights

In the latest trading session, Moderna (MRNA) closed at $51.38, marking a -1.89% move from the previous day.

Promising Biotech Stocks To Follow Today - March 20th

Danaher, Vertex Pharmaceuticals, and Moderna are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that...

Vertex Stock Falls 4.8% in a Month: Buying Opportunity or Red Flag?

VRTX stock slips nearly 5% as concerns over new drug uptake and pipeline setbacks weigh, even as its dominant CF franchise continues to drive steady growth.

<ul class="summary-bullets"><li>The therapy also gained momentum in the U.S. after NCCN added it as a treatment option for papillary bladder cancer patients unresponsive to BCG.</li><li>ImmunityBio has resubmitted its FDA application to expand Anktiva’s use, backed by clinical data showing strong cancer-free and bladder preservation rates.</li><li>The company is advancing Anktiva globally, with lung cancer trials underway and recent approvals in markets including Saudi Arabia.</li></ul>Shares of ImmunityBio, Inc. (IBRX) are set to snap a two-week losing streak after its cancer therapy Anktiva appeared on Macau’s latest drug list, adding to fresh momentum from a U.S. guideline expansion.<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> has gained over 5% this week, snapping a two-week losing streak that had erased nearly 15% of its value.<h2 class="st-heading-2">Anktiva Added To Macau Approved List</h2>Anktiva, which is available under the generic name Nogapendekin alfa, is an immunotherapy that helps activate the body’s immune system to better fight cancer. It is approved in the U.S. for use with standard BCG treatment in patients with a type of bladder cancer that no longer responds to BCG, including those with or without certain tumor growths.The Macau filing, with data as of March, lists Anktiva as a bladder cancer treatment, identifying Nogapendekin alfa as its active ingredient and noting it is given as an injection for bladder cancer. The list also includes therapies approved by regulators such as the U.S. Food and Drug Administration (FDA), China’s National Medical Products Administration (NMPA), and the European Medicines Agency (EMA).Anktiva’s inclusion places it alongside a roster of globally approved therapies from major drugmakers, including Bristol Myers Squibb, Eli Lilly, Vertex Pharmaceuticals, Janssen, Gilead Sciences, and Moderna, positioning it among established treatments across oncology and specialty care.<h2 class="st-heading-2">NCCN Expansion Adds To Momentum</h2>The Macau development comes in the same week that Anktiva was added to updated U.S. treatment guidelines. The National Comprehensive Cancer Network (NCCN) added Anktiva, used with BCG, as an “other recommended” option for patients with papillary bladder cancer that no longer responds to BCG and has not spread into muscle tissue.Earlier versions of the guidelines had included the therapy only for carcinoma in situ. The update expands the potential patient population under clinical guidance, even as the indication is not yet formally approved by the FDA.<h2 class="st-heading-2">Anktiva Seeks Label Expansion</h2>ImmunityBio is seeking to expand Anktiva’s label to include papillary bladder cancer and has&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-declines-immunitybio-resubmits-anktiva-application-to-fda/cZdVj9URIIL">resubmitted</a> its supplemental biologics license application to the FDA after previously receiving a refusal-to-file letter. The filing includes additional data requested by the agency, including updated efficacy results and long-term follow-up.Clinical data from the Phase 2/3 Quilt 3.032 study showed that 58.2% of patients remained cancer-free at 12 months, while more than 80% avoided bladder removal surgery over a three-year follow-up period, according to the company.<h2 class="st-heading-2">Global Push For Anktiva Grows</h2>Beyond bladder cancer, ImmunityBio is advancing Anktiva in lung cancer, with two pivotal trials underway in first-line and second-line non-small cell lung cancer. The company said multiple countries have expressed interest in the program as it explores broader regulatory pathways.The therapy has already received authorizations in the U.K., Europe and Saudi Arabia. In January, Saudi regulators granted approvals covering both bladder cancer and metastatic non-small cell lung cancer, including use in combination with checkpoint inhibitors.ImmunityBio said product shipments are ready to begin for a Saudi launch of Anktiva for bladder cancer, following regulatory approvals, and that it has partnered with regional distributors to expand access across the Middle East and North Africa.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for IBRX slid to ‘bearish’ from the ‘extremely bullish’ zone over the past three months amid over a 300% surge in message volumes over the same period.<figure class="image"><img src="https://news.stocktwits-cdn.com/ibrx_ss_png_ba9f17d55e.webp" alt="ibrx ss.png" width="963" height="143"><figcaption>IBRX sentiment and message volume as of March 20 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/cyberInvest/message/648013012">said</a>, “Macau - China. I’d say that’s kinda global. And unstoppable.”<stembedurl>https://stocktwits.com/cyberInvest/message/648013012</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/cyberInvest/message/648034961">said</a>, “with NMPA - Macau - China approval apparent, FDA needs to get with it. This level of disfunction is a national embarrassment. China approves before US for a US company??? This is like a Saturday Night Live skit.”<stembedurl>https://stocktwits.com/cyberInvest/message/648034961</stembedurl>IBRX stock has more than tripled over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the ImmunityBio logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

IBRX Stock Set To Snap 2 Weeks In Red: Anktiva Joins Global Blockbusters On Macau Drug List 

IBRX Stock - Anktiva, an immunotherapy for bladder cancer, was listed in Macau’s March filing alongside globally approved drugs from major pharma players.

Equity

Anktiva, an immunotherapy for bladder cancer, was listed in Macau’s March filing alongside globally approved drugs from major pharma players.

Pfizer vs Moderna: Which Pharma Stock Has More Upside?

Key PointsThe smaller, more volatile of these two companies has higher potential for significant gains...

Promising Biotech Stocks To Follow Now - March 19th

Danaher, Vertex Pharmaceuticals, argenex, Moderna, and United Therapeutics are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that develop, manufacture, or commercialize biological products and technologi...

Why Is Krystal Biotech (KRYS) Down 11.5% Since Last Earnings Report?

Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

MRNA
Moderna Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MRNA News

MRNAModerna Inc